nach oben

European Journal of Drug Metabolism and Pharmacokinetics

Erschienen in:

01.04.2018 | Original Research Article

Pharmacokinetic–Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity

verfasst von: Keizo Fukushima, Akira Okada, Hiroyuki Oe, Mika Hirasaki, Mami Hamori, Asako Nishimura, Nobuhito Shibata, Nobuyuki Sugioka

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Forced diuresis, high-volume hydration with diuresis, is widely used as a prophylactic treatment against cisplatin nephrotoxicity. However, the details of the underlying mechanisms and the optimal protocol of forced diuresis remain unclear. The present study investigated the alterations in pharmacokinetics and pharmacodynamics (nephrotoxicity) of cisplatin with forced diuresis treatment.

Methods

Cisplatin (5 mg/kg) was intravenously injected to rats (5 rats/group, except for control group in pharmacodynamic study, n = 13) treated with or without forced diuresis 2-h pre- and post-hydration with 10% mannitol at different infusion rates (0.3, 1.0, and 3.0 mL/h). The unbound cisplatin concentrations in plasma and urine, and the platinum amount in the kidney were monitored in the pharmacokinetic studies. The plasma creatinine concentration was evaluated as an index of nephrotoxicity in the pharmacodynamic studies.

Results

Forced diuresis treatment did not significantly alter the plasma cisplatin pharmacokinetics but dramatically decreased the urine concentration of unbound cisplatin and its accumulation into the kidneys in a dose-dependent manner, and correspondingly, nephrotoxicity was dose-dependently attenuated by forced diuresis. The pharmacokinetic–pharmacodynamic analysis suggested that the urine cisplatin concentration has a comparable impact on the cisplatin-induced nephrotoxicity to that in plasma, probably owing to the reabsorption of cisplatin from urine, which can be attenuated by forced diuresis.

Conclusions

These results indicated that the nephroprotective effect of forced diuresis is a pharmacokinetic-based drug–drug interaction possibly due to the inhibition of cisplatin reabsorption from urine. Monitoring of urine cisplatin concentration may lead to the optimization of a forced diuresis protocol with mannitol.

Whitehorn H, Sibanda M, Lacerda M, Spracklen T, Ramma L, Dalvie S, Ramesar R. High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa. S Afr Med J. 2014;104(4):288–91.CrossRefPubMed

Sprauten M, Darrah TH, Peterson DR, Campbell ME, Hannigan RE, Cvancarova M, Beard C, Haugnes HS, Fosså SD, Oldenburg J, Travis LB. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012;30(3):300–7.CrossRefPubMed

Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep. 1983;67(2):169–72.PubMed

McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK, Khuri FR, Shin DM, Saba NF. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer. 2015;24(4):1789–93.CrossRefPubMed

Lavolé A, Danel S, Baudrin L, Gounant V, Ruppert AM, Epaud C, Belmont L, Rosencher L, Cadranel J, Milleron B. Routine administration of a single dose of cisplatin ≥75 mg/m² after short hydration in an outpatient lung-cancer clinic. Bull Cancer. 2012;99(4):E43–8.PubMed

Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007;93(2):138–44.CrossRefPubMed

Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40(4):293–308.CrossRefPubMed

Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol. 2016;21(1):81–7.CrossRefPubMed

Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52(1):13–8.CrossRefPubMed

10.

Ruggiero A, Rizzo D, Trombatore G, Maurizi P, Riccardi R. The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not? Cancer Chemother Pharmacol. 2016;77(1):19–26.CrossRefPubMed

11.

Morgan KP, Buie LW, Savage SW. The role of mannitol as a nephroprotectant in patients receiving cisplatin therapy. Ann Pharmacother. 2012;46(2):276–81.CrossRefPubMed

12.

Latcha S, Jaimes EA, Patil S, Glezerman IG, Mehta S, Flombaum CD. Long-term renal outcomes after cisplatin treatment. Clin J Am Soc Nephrol. 2016;11(7):1173–9.CrossRefPubMedPubMedCentral

13.

Faig J, Haughton M, Taylor RC, D’Agostino RB Jr, Whelen MJ, Porosnicu Rodriguez KA, Bonomi M, Murea M, Porosnicu M. Retrospective analysis of cisplatin nephrotoxicity in patients with head and neck cancer receiving outpatient treatment with concurrent high-dose cisplatin and radiotherapy. Am J Clin Oncol. 2016;. doi:10.1097/COC.0000000000000301 (Epub ahead of print).PubMedPubMedCentral

14.

Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86(4):396–402.CrossRefPubMedPubMedCentral

15.

Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 2010;80(11):1762–7.CrossRefPubMed

16.

Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury. J Pharmacol Sci. 2006;100(1):65–72.CrossRefPubMed

17.

Schweyer S, Soruri A, Meschter O, Heintze A, Zschunke F, Miosge N, Thelen P, Schlott T, Radzun HJ, Fayyazi A. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer. 2004;91(3):589–98.CrossRefPubMedPubMedCentral

18.

Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatin-induced acute renal failure is associated with an increase in the cytokines interleukin (IL)-1beta, IL-18, IL-6, and neutrophil infiltration in the kidney. J Pharmacol Exp Ther. 2007;322(1):8–15.CrossRefPubMed

19.

Frick GA, Ballentine R, Driever CW, Kramer WG. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treat Rep. 1979;63(1):13–6.PubMed

20.

Daugaard G, Holstein-Rathlou NH, Leyssac PP. Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. J Pharmacol Exp Ther. 1988;244(3):1081–5.PubMed

21.

Fukushima K, Okada A, Sasaki K, Kishimoto S, Fukushima S, Hamori M, Nishimura A, Shibata N, Shirai T, Terauchi R, Kubo T, Sugioka N. Population pharmacokinetic-toxicodynamic modeling and simulation of cisplatin-induced acute renal injury in rats: effect of dosing rate on nephrotoxicity. J Pharm Sci. 2016;105(1):324–32.CrossRefPubMed

22.

Miura K, Goldstein RS, Pasino DA, Hook JB. Cisplatin nephrotoxicity: role of filtration and tubular transport of cisplatin in isolated perfused kidneys. Toxicology. 1987;44(2):147–58.CrossRefPubMed

23.

Nagai N, Ogata H. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats. J Pharm Sci. 1996;85(7):720–4.CrossRefPubMed

24.

Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull. 2005;28(8):1385–8.CrossRefPubMed

25.

Okuda M, Tsuda K, Masaki K, Hashimoto Y, Inui K. Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. Toxicol Lett. 1999;106(2–3):229–35.CrossRefPubMed

26.

Endo T, Kimura O, Sakata M. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line. Toxicology. 2000;146(2–3):187–95.CrossRefPubMed

27.

Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer. 1993;67(6):1171–6.CrossRefPubMedPubMedCentral

28.

Dave RA, Morris ME. Semi-mechanistic kidney model incorporating physiologically-relevant fluid reabsorption and transporter-mediated renal reabsorption: pharmacokinetics of γ-hydroxybutyric acid and l-lactate in rats. J Pharmacokinet Pharmacodyn. 2015;42(5):497–513.CrossRefPubMedPubMedCentral

29.

Polycarpe E, Arnould L, Schmitt E, Duvillard L, Ferrant E, Isambert N, Duvillard C, Beltramo JL, Chevet D, Chauffert B. Low urine osmolarity as a determinant of cisplatin-induced nephrotoxicity. Int J Cancer. 2004;111(1):131–7.CrossRefPubMed

30.

Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik PH. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep. 1981;65(1–2):73–8.PubMed

31.

32.

Williams RP Jr, Ferlas BW, Morales PC, Kurtzweil AJ. Mannitol for the prevention of cisplatin-induced nephrotoxicity: a retrospective comparison of hydration plus mannitol versus hydration alone in inpatient and outpatient regimens at a large academic medical center. J Oncol Pharm Pract. 2017;23(6):422–8.CrossRefPubMed

33.

Mach CM, Kha C, Nguyen D, Shumway J, Meaders KM, Ludwig M, Williams-Brown MY, Anderson ML. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity. J Clin Pharm Ther. 2017;42(3):286–91.CrossRefPubMed

Titel: Pharmacokinetic–Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity
verfasst von: Keizo Fukushima
Akira Okada
Hiroyuki Oe
Mika Hirasaki
Mami Hamori
Asako Nishimura
Nobuhito Shibata
Nobuyuki Sugioka
Publikationsdatum: 01.04.2018
Verlag: Springer International Publishing
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 2/2018
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-017-0436-8

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Pharmacokinetic–Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity

Abstract

Background and Objectives

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background and Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Correction to: Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis

In Vitro Comparison of the Role of P-Glycoprotein and Breast Cancer Resistance Protein on Direct Oral Anticoagulants Disposition

Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients

Pharmacokinetic Study of Piracetam in Focal Cerebral Ischemic Rats

Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study